2026 patient survey on kidney cancer and renal masses by the International Kidney Cancer Coalition (IKCC).
On Friday, October 9, 2026, the Latin American Renal Cancer Group (LARCG) held its 2nd Annual Meeting in person in Lima, Peru, as part of the XLV Congress of the American Confederation of Urology (CAU Peru 2026).
The event took place at the Lima Convention Center (LCC), specifically in the Armatambo Room (4th Floor), from 09:00 to 10:30 hrs, gathering leading specialists from across the region.
The academic agenda featured high-level technical and scientific presentations delivered by experts from the region:
09:00 – 09:05 | Opening and Welcome
Dr. Diego Abreu (CASMU, Uruguay)
09:05 – 09:20 | Active Surveillance in Small Renal Masses (“LARCG Experience”)
Dr. Ignacio Tobia (Hospital Italiano, Argentina)
09:25 – 09:40 | Inferior Vena Cava Thrombus in RCC
Dr. Ruben Bengió (Córdoba, Argentina)
09:45 – 10:00 | Technical Details of Robotic Surgery in Endophytic Renal Tumors
Dr. Clovis Fraga (Recife, Brasil)
10:05 – 10:20 | Cytoreductive Nephrectomy: Current Role?
Dr. Rodolfo Borges dos Reis (Ribeirão Preto, Brasil)
10:25 – 10:30 | Conclusion and Closing Remarks
The 57th International Urology Course of the Fundació Puigvert will take place from October 16 to 18 of this year, 2024, with a new venue, the Ramblas room of the Hilton Hotel in Barcelona. Under the motto “Expanding knowledge through dialogue” it will promote the exchange of knowledge and experiences with a common goal: to advance the treatments and care of our specialty.
The program will intersperse live surgeries, pre-recorded surgeries, conferences, sessions with experts and round tables where current scientific topics will be discussed.
The AUA invites the global urologic community to the 119th AUA Annual Meeting in the dynamic city of San Antonio, TX!
AUA2024 Features In-person and Virtual Registration Options!
Whether you prefer to attend in-person in San Antonio or virtually from home, the AUA offers both live and virtual registration options to meet your learning needs.
We learned so much and leave determined to continue moving the needle in kidney cancer treatment and empowering patients and families to get the care they deserve. #unstoppabletogether
1955 – 2022
His inclusive vision was a fundamental pillar in the creation and dissemination of the first Latin American group in kidney cancer.
Members of LARCG
This year’s American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium was held both virtually and face-to-face. The presentations are available to view on the ASCO website. The International Kidney Cancer Coalition (IKCC) reviewed the virtual scientific programme to keep abreast of the latest advances in the care and treatment of patients with kidney cancer.
Address: 555 Canal St, New Orleans, LA 70130, US
Welcome / Opening and Registration
Stênio C Zequi / Diego Abreu / Ana Maria Autran / Jose Ignácio Nolazco / Ignacio Pablo Tobia / Francisco Covarrubias
LARCG Database/ LARCG Web site
Diego Abreu – Pasteur Hospital Uruguay
Nephrectomy for metastatic kidney cancer in the era of check point inhibitor
Axel Bex – The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam.
Actualization of GWAS- study- from National Cancer Institute/ National Institute of Health-NCI-NIH & LARCG
Dr. Mark Purdue – Epidemiology Department NHI/NCI-National Institute of Health – National Cancer Institute-US.
Retroperitonial Robotic Partial Nephrectomy
Alberto Breda – Chief of the Uro-Oncology Division and of the Kidney Transplant Unit at Fundacio Puigvert. Chairman of EAU Robotic Urology Section (ERUS)
Level 3-4 Vena Cava thrombus in kidney cancer: open approach
Gaetano Ciancio – Department of Urology, University of Miami Miller School of
Medicine, Jackson Memorial Hospital, Miami, Florida, USA.
Patient-derived renal cell carcinoma xenografts capture tumor genetic profiles and aggressive behaviors
Stenio de Cássio Zequi – A.C. Camargo Cancer Center Referral Center for Urological Tumors &CIPE- International Research Center- São Paulo-Brazil
Systemic Therapies for metastatic clear cell RCC- A step by step update for surgeons
Benjamin Maughan – Huntsman Cancer Institute – University of Utah
3D video laparoscopic surgery for renal cell carcinoma
Fernando Kim – Denver Health Medical Center- University of Denver Colorado US
Systemic Therapies for metastatic non clear cell RCC- An update
Benjamin Maughan – Huntsman Cancer Institute- University of Utah
VHL and renal cell carcinoma: Brazil and Latin American Scenario and the management changes in the urological practice after MK-6482 (Belzutifan) use
José Cláudio Casale da Rocha – Department of Oncogenetics – A. C. Camargo Cancer Center
Pure laparoscopic for advanced renal cell carcinoma: Actual scenario
Diego Abreu – Pasteur Hospital –Montevideo- Uruguay
A tribute to Mario Guillermo Carlos Gueglio Saccone
Alberto Jurado – Hospital Italiano Buenos Aires
Small Renal Masses-Active surveillance LARCG Protocol Study Actualization
Ignacio Pablo Tobia – Hospital Italiano Buenos Aires
Discussion and Closure
Advocacy News in Kidney Cancer: LARCG & IKCC International kidney Cancer
Coalition & 2022 Kidney Cancer Day
Stênio de Cássio Zequi & Francisco Covarrubias – Mexico
To assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries.
Of 4,060 patients with renal cell carcinoma diagnosed between 1990 and 2015, a total of 530 (14.5%) had metastasis at clinical presentation. Relationships between clinical and pathological parameters and treatment-related outcomes were analyzed by Cox regression and the log-rank method.
Of 530 patients, 184 (90.6%) had died of renal cell carcinoma. The median OS of the entire cohort was 24 months. American Society of Anesthesiology classification 3-4 (hazard ratio [HR]: 1.64), perirenal fat invasion (HR: 2.02), and ≥ 2 metastatic organ sites (HR: 2.19) were independent prognostic factors for 5-year OS in multivariable analyses. We created a risk group stratification with these variables: no adverse risk factors (favorable group), median OS not reached; one adverse factor (intermediate group), median OS 33 months (HR: 2.04); and two or three adverse factors (poor risk group), median OS 14 months (HR: 3.58).
Our study defines novel prognostic factors that are relevant to a Latin American cohort. With external validation, these easily discerned clinical variables can be used to offer prognostic information across low- and middle-income countries.
1. Valoración multimétodo de una lesión renal mesorrenal izquierda, posterior, con un crecimiento predominante exofítico. La lesión es hipointensa en T2, sin un componente graso macro o microscópico y con marcada restricción en secuencia de difusión, sugestivo de hipercelularidad. Tras la administración de contraste ev., su realce es tenue y progresivo. En tomografía se objetiva hipodensa y cont tenue realce. Se realizaron reconstrucciones 3D e impresión 3D como parte de la valoración pre-quirúrgica. La lesión correspondía a un carcinoma papilar tipo II. Hospital Británico de Buenos Aires, Argentina.
2. Lesión quística en el polo superior del riñón derecho, con dos engrosamientos parietales, de morfología nodular, que muestran realce post-contraste ev. Se realizaron reconstrucciones 3D como parte de la valoración prequirúrgica. Hospital Británico de Buenos Aires, Argentina.
3. Recurrencia local de carcinoma renal de células claras en el sitio quirúrgico de nefrectomía parcial. Se observa un lesión sólida mesorrenal. Se realiza reconstrucción 3D como parte de la valoración pre-quirúrgica y su correlación con la pieza de nefrectomía. Hospital Británico de Buenos Aires, Argentina.